HIGHLIGHTS
- who: Xiang Gao from the of Giessen, Germany have published the paper: PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer, in the Journal: (JOURNAL) of 30/04/2022
- what: The authors investigated PCSK9 expression by immunohistochemistry in tumor tissue from advanced NSCLC patients before receiving anti-PD-1 immunotherapy. The work demonstrated that aside from being related to poor response, high PCSK9 expression in baseline NSCLC tissues was also an independent risk factor for both PFS and OS in advanced NSCLC patients with antiPD-1 immunotherapy.
- how: In parallel considering . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.